STTK

Shattuck Labs, Inc. (STTK) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases. The company's lead program is SL-325, a first-in-class death receptor 3 (DR3) antagonist antibody for inflammatory bowel disease (IBD). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 66.6% in Q3 and 82.5% YTD compared to 2024. This is primarily due to the completion of all obligations under prior collaboration agreements with Ono Pharmaceutical and ImmunoGen in 2024. The 2025 revenue consists solely of a $1.0 million non-cash license fee from Kayak Therapeutics.
• Expense Reduction: Operating expenses decreased significantly. R&D expenses dropped 53.3% in Q3 and 49.4% YTD. This reduction is driven by the discontinuation of the SL-172154 program, workforce reductions, and the termination of the Ono collaboration.
• Improved Loss Profile: Net loss narrowed by 39.7% in Q3 and 36.2% YTD, reflecting the substantial decrease in operating costs.
• Capital Raise: In August 2025, the company raised approximately $44.5 million (net) through a private placement of common stock, pre-funded warrants, and common stock warrants.

Outlook, Risks, and Management Commentary

• Liquidity Runway: Management believes current cash, cash equivalents, and short-term investments ($86.1 million) are sufficient to fund operations for at least the next 12 months. Including potential proceeds from the full exercise of outstanding warrants, the company estimates funding into 2029.
• SL-325 Progress: The company has initiated enrollment in the Phase 1 clinical trial for SL-325 and expects to complete enrollment in Q2 2026.
• Nasdaq Compliance: The company received notice in August 2025 regarding non-compliance with the minimum bid price requirement ($1.00). Compliance was regained on September 16, 2025.
• Key Risks:
  • Government Shutdown: A U.S. federal government shutdown began October 1, 2025, potentially delaying FDA reviews and regulatory submissions.
  • Financing Needs: The company remains dependent on additional equity or debt financing to complete development. Future funding may not be available on acceptable terms.
  • Warrant Exercise Uncertainty: The company holds significant outstanding warrants (52.6 million common stock warrants). Proceeds are not guaranteed as holders may exercise cashless or not at all.
  • ATM Facility: The At-The-Market (ATM) facility is currently inactive as the Form S-3 registration statement expired on July 29, 2025.

Investor Verification Checklist

• Warrant Terms: Verify the exercise price ($1.0846) and expiration conditions (tied to Phase 1 data announcement) for the 52.6 million outstanding common stock warrants.
• SL-325 Trial Status: Monitor enrollment progress for the Phase 1 trial and the timeline for data readout, which triggers warrant expiration.
• Regulatory Environment: Assess the impact of the ongoing U.S. government shutdown on FDA review timelines for future INDs or clinical trial approvals.
• Capital Structure: Review the dilution impact of the 37.4 million pre-funded warrants and 52.6 million common stock warrants outstanding.
• Revenue Sustainability: Confirm the absence of recurring revenue streams, as 2025 revenue was a one-time non-cash license fee.